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Abstract. To improve the poor water solubility and dissolution rate of the oral hypoglycemic drug
glibenclamide, it was molecularly dispersed in Neusilin® UFL2, an amorphous synthetic form of magne-
sium aluminometasilicate, at different proportions; the physicochemical and biopharmaceutical proper-
ties, as well as the stability of the four different batches recovered were characterised, and it was
determined that complete dispersion of glibenclamide in the amorphous polymer was obtained at the
drug to Neusilin ratio of 1 to 2.5. Completely amorphous dispersion was proven by Thermal Analysis and
X-Ray Powder Diffractometry. Very small particles were obtained, ranging from approximately 200 to
400 nm. The amorphous batches were physically and chemically stable for the entire duration of
experiments. The physicochemical properties of the four batches were compared to those of the starting
materials and physical mixtures of Neusilin® UFL2 and glibenclamide, the latter showing the typical
behaviour of simple mixes, i.e., the additivity of properties of single components. The dissolution studies
of the four solid dispersions revealed a very high dissolution rate of the completely amorphous batches
(Batches 3 and 4), behaviour that was ascribed to their high Intrinsic dissolution rate due to the
amorphous characteristics of the solid dispersions, to their very small particle size, and to the presence
of polysorbate 80 that improved solid wettability. The technique under investigation thus proved effective
for recovering stable amorphous dispersions of very small particle sizes.
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INTRODUCTION
Glibenclamide (GLB), an oral hypoglycemic drug in the
sulfonylureas class, is widely used for the treatment of type 2
diabetes (1). It is a poorly water soluble active pharmaceutical
ingredient (∼38 μmol/L at 37°C) (2). with poor bioavailability
after oral administration (3–5). Several attempts were made to
improve GLB particle dissolution and bioavailability, by mod-
ifying the crystalline form (6). through controlled crystalliza-
tion (7). by complexation with cyclodextrines (8) or by solid
dispersions (9). and by producing nanocrystals (10,11).
Solid dispersion, the dispersion of drugs in an amorphous
matrix, has been considered by many as an efficient method
for improving drug solubility and/or dissolution rate (12–15),
according to the Noyes-Whitney law (16).
However, even though the drug is molecularly dispersed
in the polymeric matrix in amorphous solid dispersions, a fact
that strongly contributes to particle dissolution, the size of the
solid particles generally ranges between approximately 3 and
10 μm (17,18). More recently and rarely, in three studies,
particles of solid dispersions have been obtained in the
nanometric size: amorphous particles in the nano-range of
sizes of felodipine and PVP were obtained because of the
strong interaction between the drug and the polymer (19).
the bioavailability of sirolimus was improved by producing
nanoparticles of drug dispersed in PVP K30 by using a super-
critical antisolvent process (20). and nanoparticle solid disper-
sions of raloxifene in PVP were prepared by using a common
spray drying technique (21).
With these factors in mind, the objective of this study was
to select an excipient and a preparation method able to yield
amorphous solid dispersions in the nanometric range.
To this end, glibenclamide was dispersed in a relatively
new amorphous material, Neusilin® UFL2, an amorphous,
synthetic form of magnesium aluminometasilicate, that is
widely used for pharmaceutical applications as a carrier and
filler for improving the quality of tablets, powders, granules
and capsules.
More recently, its use has been proposed in solid disper-
sions because of its ability to favor the amorphisation of drugs
under co-grinding (22–25) and hot-melt granulation (26–28).
Thus the objective of this study was to obtain amorphous
solid dispersion of glibenclimide in Neusilin® UFL2 with par-
ticle sizes in the nanometric range.
MATERIALS AND METHODS
Materials
Glibenclamide (GLB) was kindly supplied by Menarini
Manufacturing Logistics and Service (Florence, Italy) as white
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crystalline powder. Native crystals are indicated as NCs in the
text and were stored in a desiccator in presence of P2O5 as
desiccant during the experiment time interval. Neusilin®
UFL2 (NEU) was kindly supplied by Seppic (Paris, France).
Ultrapure water was produced by the Gradient Milli-Q®
(Millipore, Molsheim, France). Chemicals, supplied by
Sigma-Aldrich (Steinheim, Germany), were all of analytical
grade. Completely amorphous glibenclamide was prepared by
quench-cooling of the melt according to Wojnarowska (29)
and stored in a desiccator in presence of P2O5 as desiccant
during the experiment time interval.
Preparation of Glibenclamide-Neusilin® UFL2 Samples
As a consequence of preliminary tests, several mixtures
of GLB and NEU were prepared at different NEU amounts to
find the ratio best able to promote the complete
amorphisation of the mixture under treatment:
Batch 1: GLB 100 mg+NEU 125 mg (1:1.25) (theoretical GLB
content 44.4% by weight);
Batch 2: GLB 100 mg+NEU 200 mg (1:2) (theoretical GLB
content 33.3% by weight);
Batch 3: GLB 100 mg+NEU 250 mg (1:2.5) (theoretical GLB
content 28.6% by weight);
Batch 4: GLB 100 mg+NEU 500 mg (1:5) (theoretical GLB
content 16.7% by weight).
All mixtures were dissolved under stirring in 20 g of
dichloromethane, and then 25 mg of polysorbate 80 were
added to the mixture to prevent particle agglomeration. The
solvent was then evaporated under reduced pressure at 35°C
(Rotavapor® R-210, Buchi, Flawil, Switzerland; vacuum
pump, V-710, Buchi, vacuum level 680 mmHg). Batches were
stored in a desiccator in presence of P2O5 as desiccant during
the experiment time interval. In addition to Batches 1–4, four
physical mixes were prepared of the same composition of
Batches 1–4. To distinguish these last products to the previ-
ously described batches, they are identified as physical mix-
tures (PMs):
PM 1: GLB 100 mg+NEU 125 mg (1:1.25);
PM 2: GLB 100 mg+NEU 200 mg (1:2);
PM 3: GLB 100 mg+NEU 250 mg (1:2.5);
PM 4: GLB 100 mg+NEU 500 mg (1:5).
They were prepared by simply mixing GLB and NEU in a
mortar and storing them in a desiccator in presence of P2O5 as
desiccant during the experiment time interval.
The physicochemical properties of all the sampleswere
evaluated using different analytical methods.
HPLC Method
The chemical stability of GLB during processing and the
GLB content in solid dispersions were evaluated through
HPLC analysis, performed using an HPLC 1090 Hewlett
Packard Series I (Ramsey, MN, USA) equipped with a
Hewlett Packard HP1100 MSD Chemstation Rev. A.08.03.
A reverse phase column was used at 25°C (C18, 250×
4.6 mm, 5 μm in particle size) (GL Science, Eindhoven,
The Netherlands). Isocratic elution with 0.1% orthophospho-
ric acid: acetonitrile: methanol 20:50:30 (V/V) was used at a
flow rate of 1.0 ml min−1. The experimental pH of the mobile
phase 5.4 was measured by a pHmeter (Jenway 3510, Essex,
England) equipped with a pH electrode (Jenway, Essex, En-
gland) calibrated with appropriate standard solutions. The
mobile phase was prepared freshly and degassed by sonicating
for 5 min before use. 1.0 mg of GLB were dissolved in 10.0 ml
of mobile phase and passed through 0.45-μm filters (Millipore,
Molsheim, France). The volume of injection was 20 μL, and
the flow rate was 1 ml min−1. Detection was done at 210 nm.
Evaluations were assessed by considering the retention time
of chromatogram peaks and peak area. Under the conditions
used, a typical GLB peak had a retention time of 2.97 min.
Scanning Electron Microscopy
Particle morphology was determined using a scanning
electron microscope (SEM) (Stereoscan 360, Cambridge In-
struments, Cambridge, United Kingdom). Samples were
mounted on a metal stub with double-sided adhesive tape
and then sputtered under vacuum with a gold layer of about
200-Å thickness using a metallizator (Balzer MED 010,
Linchestein). The particle size of coarse GLB native crystals
(size >3.0 μm) was determined by measuring the Ferret’s
diameter of 500 particles.
Dynamic Light Scattering Analysis
Particle size in the nanometric range was determined by
Dynamic Light Scattering (DLS) (Zetasizer Nano S90,
Malvern Instruments, Worcestershire, UK), by dispersing par-
ticles in water by vortexing or sonication. During the analyses,
the attenuation and the polydispersity index were checked to
verify the appropriateness of the measurements.
Thermogravimetric Analysis
Thermogravimetric analysis was used to determine the
sample water content and was carried out by Simultaneous
Thermal Analysis (Simultaneous Thermal Analyser, STA
6000, Perkin Elmer, Inc., Waltham, Massachusetts, USA),
under nitrogen atmosphere (20 ml min−1) in 0.07 ml open
aluminium oxide pans. STA was calibrated for temperature
and heat flow with three standard metals (tin, indium and
zinc), taking into account their expected melting temperatures
(231.93, 156.60, 419.53°C, respectively), and for weight with an
external Perkin Elmer standard (Calibration Reference
Weight P/N N520-0042, Material lot 91101 GB, Weight
55.98 mg, 01/23/08 VT). Calibration was repeatedly checked
to assure deviation ≤± 0.3°C. Samples were heated from room
temperature to 190°C at a heating rate of 10°C min−1.
Differential Scanning Calorimetry Analysis
Differential Scanning Calorimetry (DSC) analysis was
performed on a Pyris 1 calorimeter (Perkin Elmer, Co. Nor-
walk, USA) equipped with a cooling device (Intracooler 2P,
Cooling Accessory, Perkin Elmer, Co. Norwalk, USA). A dry
purge of nitrogen gas (20 ml min−1) was used for all runs. DSC
was calibrated for temperature and heat flow using a pure
sample of indium and zinc standards. Sample mass was about
4–5 mg, and aluminium perforated pans of 50 μl were used.
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Samples were heated from room temperature to 190°C at a
heating rate of 10°C min−1.
The DSC was carried out to characterise the sample solid
state and the degree of crystallinity; the latter was calculated
by taking into account the melting enthalpy value of the pure
100% crystalline form (GLB native crystals) and the relative
enthalpy value of samples under investigation.
X-Ray Powder Diffractometry
To assess the solid state of the studied samples and to
follow their physical stability, X-ray powder diffractometry
(XRPD) was used. A Philips PW 1730 (Philips Electronic
Instruments Corp., Mahwah, NJ, USA) model was used as
X-ray generator for Cu Kα radiation (λα1=1.54056 Å, λα2=
1.54430 Å), and the experimental X-ray powder patterns were
recorded on a Philips PH 8203 recorder. The goniometer
supply was a Philips PW 1373, and the channel control was a
Philips PW 1390. Data were collected in the discontinuous
scan mode using a step size of 0.01° 2α. The scanned range
was 2 θ to 40° (2 θ).
The crystallinity degree of powders was evaluated by
XRPD and calculated according to a previously described
method (30). Briefly, a calibration curve was determined from
physical mixtures of pure GBC considered completely crystal-
line (100% crystalline), and GBC obtained from quench-
cooling procedure considered completely amorphous (100%
amorphous). The calibration curve was determined, in pres-
ence of an internal standard, by calculating the total area
(Atot) of the diffraction patterns (crystalline + amorphous)
and the area (ACr) of the crystalline part (the area over the
peak baseline). The powder crystallinity degree was expressed
according to the following Eq. (1):
Crystallinity %ð Þ ¼ ACr
Atot
 100 ð1Þ
The crystallinity degree was the average value of three
different measurements. The statistical significance was eval-
uated by a One-Way ANOVA test for α=0.05.
Intrinsic Dissolution Rate Study
The intrinsic dissolution study was carried out by the
rotating disk method (31) on native GLB and the four Batches
1–4. Thirteen-mm diameter tablets were obtained by
compressing 300 mg of powder in a Perkin-Elmer hydraulic
press for IR spectroscopy KBr disks, at a force of 15 kN for
10 min. This process yielded tablets with a surface area of
132.73 mm2 that would not disintegrate during the test. Tab-
lets were inserted into a stainless steel holder, so that only one
face was exposed to the dissolution medium. The holder was
then connected to the stirring motor of a dissolution apparatus
(Erweka DT6, Gloucestershire, England), centrally immersed
in a 1000-ml beaker containing 900 ml of phosphate buffer
(pH 7.2) (buffer solution, USP Pharmacopoeia) at 37°C and
rotated at 100 rpm. Suitable aliquots were withdrawn with a
regenerated cellulose filter syringe (0.45 μm; Filalbet, Rosello,
Spain) at specified times and assayed for drug content spec-
trophotometrically at a wavelength of 457 nm. A correction
was calculated for cumulative dilution caused by replacement
of the sample with an equal volume of original medium. Each
test was repeated six times. Low standard deviations were
obtained, indicating the good reproducibility of this technique.
The intrinsic dissolution rates (IDR) were calculated from the
slope of the straight line of cumulative drug release.
Dissolution from the Particle Samples
Particle dissolution of native GLB and Batches 1–4 was
carried out in a 1000-ml beaker containing 900 ml of phos-
phate buffer (pH 7.2) at 37°C and rotated at 50 rpm (Erweka
DT6, Gloucestershire, England); sink conditions were assured
during the experiments. Suitable aliquots were withdrawn
with a regenerated cellulose filter syringe (cellulose acetate
of 0.45 μm, Filalbet, Barcelona, Spain) at specified times and
assayed for drug content spectrophotometrically at a wave-
length of 457 nm. A correction was calculated for cumulative
dilution caused by replacement of the sample with an equal
volume of original medium. Each test was repeated six times.
Low standard deviations were obtained, indicating the good
reproducibility of this technique. Results were expressed as
percentage of total drug release.
Long-Term Stability Study
The long term stability study (12 months) was carried out
according to the ICH (stability testing of new drug substances
and products, Q1A(R2)) (32) by storing samples in tightly
closed glass containers at 25°C±2°C/60% RH±5% RH. The
stability was evaluated by measuring the particle size and by
assessing changes in the physical solid form of the GBC sam-
ples. In addition, changes in dissolution behaviour were mea-
sured by IDR and dissolution test.
Statistical Analysis
The crystallinity degree, dissolution data, and particle size
were analysed by one-way analysis of variance (ANOVA),
using a Bonferroni test. The statistical analysis was conducted
using an Origin® software (version 8.5) (Northampton, Mas-
sachusetts, USA). Results are shown as mean±SD (standard
deviation) and considered significantly different when P<0.05.
RESULTS AND DISCUSSION
Physicochemical Characterisation of Glibenclimide Samples
Native GLB crystals appeared as irregular parallelepi-
peds (Fig. 1a). Coarse particles coexisted with smaller irregu-
lar particles. The mean geometric particle diameter was
approximately 32.23±2.91 μm (Table I).
Amorphous GLB appeared as irregular particles
characterised by smoothed edges (Fig. 1b). The mean geomet-
ric particle diameter was approximately 2.80±0.34 μm
(Table I).
In Neusilin® UFL2, large spherical agglomerates
coexisted with small irregular ones, probably formed from
the breakage of the spherical agglomerates (Fig. 1c). The
mean geometric particle diameter was 7.78±4.25 μm (Table I).
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Four physical mixtures of GLB-NEU were prepared
(PMs 1, 2, 3 and 4) and analysed under scanning electron
microscopy (Fig. 1d–g). In the photomicrographs, large
particles of GLB or agglomerated of Neusilin are dispersed
in smaller particles. Four batches of solid dispersions of
different ratios of glibenclamide and Neusilin® UFL2 were
prepared. Particles of Batch 1 (GLB-NEU 1:1.25 ratio)
(Fig. 1h) appeared irregular and isodimensional and were
characterised by quite smooth, round edges. Some coarse
particles existed and were grouped with smaller particles.
The crystallization procedure strongly reduced the particle
size (0.52±0.41 μm) compared to the original particles.
Batch 2 (GLB-NEU 1:2) (Fig. 1i) had irregular and round
small particles. Coarser ones disappeared and a more ho-
mogeneous particle distribution could be observed. The
mean geometric particle size was reduced to 0.39±
0.10 μm. Far smaller particle size (0.29±0.22 μm) and
narrow particle distribution was highlighted for Batch 3
(GLB-NEU 1:2.5) (Fig. 1l), which had isodimensional,
round and smooth particles. The particle shape and distri-
bution of Batch 4 (GLB-NEU 1:5) (Fig. 1m) were similar
to those of Batch 1; the particles in this last batch were still
round and irregular, and had coarse particles in presence
of small ones (0.47±0.42 μm). DSC analysis (Fig. 2) of
pure GLB made it possible to evaluate its thermal behaviour
by calculating the extrapolated onset temperature (175.89±
0.63°C) and the enthalpy content (95.34±4.29 J g−1) of the
melting peak (Table II). The water content (0.77±1.22%) was
consistent with an anhydrous solid (Table II). The 100% crys-
tallinity degree was assigned to this sample.
In the DSC thermogram (Fig. 2) of amorphous GLB, the
only glass transition temperature at nearly 62.20±1.30°C in
accordance to Wojnarowska (29) was observed. The water
content (7.24±1.13%) was consistent with an amorphous ma-
terial characterised by a certain tendency to retain water
(Table II).
Fig. 1. SEM microphotographs of glibenclamide samples. a Native crystals (1000x); b Amorphous
glibenclamide (3500x); c Pure Neusilin® UFL2 (2500x); d Physical Mixture PM 1 (2500x); e Physical Mixture
PM 2 (2500x); f Physical mixture PM 3 (2500x); g Physical mixture PM 4 (2500x); h Batch 1 (8000x); i Batch 2
(8000x); l Batch 3 (8000x); m Batch 4 (8000x)
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The thermogram of pure Neusilin (Fig. 2) was
characterised by a broad endotherm between 40 and 130°C
due to the loss of hydration water from the amorphous mate-
rial. The loss of water from NEU was 4.47±0.75%, a value
that is in agreement with the NEU technical document
(Table II).
DSC thermograms of all the four batches of GLB-
NEU did not exhibit melting peaks. In Fig. 2, the thermo-
Fig. 1. (continued)
Table I. Geometric Mean Particle Size of Glibenclamide Samples Determined at Time 0 (t0) and After 12 Months (t1). All the Samples were
Stored in a Desiccator in Presence of P2O5 as Desiccant During the Experiment Time Interval
Time 0 Time 12 months
Mean geometric particle
diameter (μm)
Polydispersity index Mean geometric particle
diameter (μm)
Polydispersity index
Native crystalsa 32.23±2.91 – 34.78±1.27 –
Amorphous GLBa 2.80±0.34 – 2.66±0.85 –
Neusilin UFL2a 7.78±4.25 – 8.57±3.12 –
Batch 1b 0.52±0.41 0.452±0.089 0.55±0.37 0.323±0.092
Batch 2b 0.39±0.10 0.248±0.043 0.41±0.12 0.267±0.033
Batch 3b 0.29±0.22 0.216±0.116 0.28±0.32 0.200±0.155
Batch 4b 0.47±0.42 0.583±0.092 0.45±0.68 0.677±0.127
aDetermined by measuring the Ferret’s diameter of 500 particles observed through the SEM analysis
bDetermined by dynamic light scattering
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gram for the Batch 3 is given as an example, the thermo-
grams of the other batches being similar. The absence of
the GLB melting peak might indicate that amorphous mix-
tures were formed at any ratio, but this preliminary con-
clusion will be contradicted by XRPD analysis. The water
content of Batches 1 to 4 could account for the hydration
into amorphous solids (Table II). The water content of
solid dispersions, ranging approximately between 5 and
9%, may depend on the amorphous state and very low
mean geometric particle size (high particle surface) of the
samples that may explain the capacity of amorphous forms
to absorb water.
The physical mixes showed a thermal behaviour compat-
ible with a physical mix. The thermogram of the PM 3 (Fig. 2e)
showed the GLB melting endotherm at 171.00±0.55°C. The
variation in enthalpy content associated to the GLB melting is
lower than the melting of the pure compound (ΔH 37.28±
2.51 J/g), as expected for a mixture.
Fig. 2. Thermograms of samples under investigation: glibenclamide native crystals (a); amorphous glibenclamide (b); pure
Neusilin® UFL2 (c); solid dispersions (Batch 3) (d); physical mixture (PM 3) (e)
Table II. Physicochemical Characterisation of Glibenclamide Samples Carried Out by Thermal Analysis and X-Ray Powder Diffractometry
(XRPD). The Extrapolated Onset Temperature (Tm) and the Enthalpy of Melting were Determined by Conventional DSC. From the Melting
Enthalpies the Crystallinity Degree of Samples were Determined Immediately After Preparation (t0) and After Storage for 12 Months (t1). The
Crystallinity Degree was Also Determined by XRPD
Glibenclamide Melting endotherma Crystallinity (%)a Crystallinity (%)b Water content (%)c GLB purity (%)d
Tm ΔH J/g t0 t1 t0 t1
Native crystals 175.89±0.63 95.34±4.29 100.0 100.0 100.0 100.0 0.77±1.22 99.98±0.10
Amorphous
glibenclamide
– – 0.0 0.0 0.0 0.0 7.24±1.13 99.95±0.20
Batch 1 – – 0.0 0.0 10.4 23.7 5.52±0.84 46.75±1.24
(44.4)e
Batch 2 – – 0.0 0.0 4.7 10.2 9.05±1.17 30.29±0.75
(33.3)e
Batch 3 – – 0.0 0.0 0.0 0.0 8.38±1.08 27.46±0.29
(28.6)e
Batch 4 – – 0.0 0.0 0.0 0.0 9.07±0.83 15.38±0.36
(16.7)e
Neusilin UFL2 – – 0.0 0.0 0.0 0.0 4.47±0.75 –
aDetermined by conventional DSC
bDetermined by XRPD
cDetermined by TGA-STA at t0
dDetermined by HPLC through the integration of the GLB peak area (peak retention time 2.97 min)
eTheoretical GLB content in the mixes
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In Fig. 3, the typical X-ray powder diffractogram of
the crystalline GLB is showed. The absence of typical
patterns of the GLB obtained by quench-cooling con-
firmed the completely amorphous character of this sample.
NEU also appeared completely amorphous. XRPD of
Batches 1–4 contradicted the preliminary results provided
by the DSC results. In fact, the existence of GLB peaks in
the Batch 1 diffractogram indicated that the mixture was
not completely amorphous. By calculating the crystallinity
degree from XRP diffractometry, it was possible to con-
clude that the degree of crystallinity was 10.4%. A slightly
lower crystallinity degree (4.7%) was observed for Batch
2. Thus, the absence of the GLB melting peak in the DSC
thermograms of Batches 1 and 2 was not due to the
completely amorphous state of the solid, but rather to
the fact that the almost amorphous mixture favoured the
complete interaction of the two compounds during heating
and led to a completely amorphous mix and the disap-
pearance of the melting peak. This behaviour is typical of
strongly interacting compounds (30).
Batches 3 and 4, on the contrary, appeared completely
amorphous also under the XRPD analysis; this evidence made
it possible to conclude that Batches 3 and 4 were completely
amorphous.
In the diffractograms of physical mixtures PM 1–4, it was
possible to identify the presence of typical diffraction peaks of
GLB, the intensity of which are proportional to the amount of
the drug into the mix.
The GLB chemical stability was evaluated by HPLC. The
integration of the GLB peak area for the native crystals and
the amorphous form ranged from 99.50 to 99.98%, indicating
the sample purity (Table II) and in particular that no degra-
dation occurred during the preparation of the GLB amor-
phous form.
The four solid dispersions (Batches 1–4) showed a GLB
content very close to the theoretical content, as reported in
Table II.
Intrinsic Dissolution Rate and Dissolution from the Particle
Samples
Intrinsic Dissolution Profiles are shown in Fig. 4. The
Intrinsic Dissolution Rates (IDRs) (Table III) were calculated
from the slope of the strength lines of cumulative drug release.
The IDR of native crystals of GLB was rather low, as expected
for a poorly soluble drug and as also previously reported (11).
The IDR strongly increased for Batches 1–4. Since as already
reported, IDR was not influenced by the particle size (33)
because differences in particle size are diminished by the high
compression pressure used to prepare sample compacts; most
likely it was influenced by the amorphous character of the
solid dispersions. In addition, it is possible to observe that the
IDRs increased in the order Batch 1<Batch 2<Batches 3 and
4, and thus proportionally to the crystallinity degree, which
was respectively 10.4, 4.7 and 0.0% (the last value for both
Batches 3 and 4). The very low differences in IDR between
Batches 3 and 4 are not statistically significant (significance
level P<0.05) (Fig. 5).
The polysorbate 80 undoubtedly favours the surface wet-
tability (33,34). and thus it concurs to improve the IDR of
Batches 1–4 with the respect to that of native crystals.
The results of particle dissolution are shown in Fig. 3. The
dissolution curves were quite similar for GLB native crystals
and Batch 1, while they increased from Batch 2 to Batch 4,
and were the best for Batch 3. These results are firstly clearly
correlated to the IDRs and thus to the crystallinity degree %,
but these parameters are not the ones that affected particle
dissolution. Actually, the fact that Batch 3 had the lowest
geometric mean particle diameter may be a significant factor
in explaining why it exhibited the best dissolution behaviour.
In addition, the contribution of polysorbate to the improved
wettability explains the better dissolution rate of solid disper-
sions that native crystals. It is also necessary to consider that in
spite of NEU being an insoluble carrier, solid dispersions, in
particular Batches 3 and 4 where the GLB is completely
amorphous, showed excellent dissolution behaviour. The
Fig. 3. X-ray powder diffraction patterns of glibenclamide batches.
(a) glibenclamide native crystals; (b) amorphous glibenclamide; (c)
Neusilin® UFL2; (d–g) solid dispersions ((d) Batch 1; (e) Batch 2; (f)
Batch 3; (g) Batch 4); (h–l) physical mixtures ((h) PM 1; (j) PM 2; (k)
PM 3; (l) PM 4)
Fig. 4. Cumulative drug release expressed versus time of
glibenclamide native crystals (NCs) and Batches 1–4 in phosphate
buffer (pH 7.2)
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improvement in dissolution behaviour of solid dispersions has
been more frequently achieved by using soluble carriers (12).
However, it is not infrequent that also insoluble carriers may
favour the dissolution rate of poorly water-soluble drugs from
solid dispersions (35,36).
When the carrier is insoluble and not swellable and
up to an appropriate drug-carrier proportion, one can
suppose that drug controls the diffusion through the car-
rier, particularly when the drug exceeds the solubility of
the carrier (37). In our case, the amorphization of the
drug improved the drug solubility with the consequence
that diffusion is controlled by the drug. At higher carrier
weight fractions, the drug release becomes controlled by
dissolution of the carrier (37) that in our case decreased
the dissolution rate. This may explain why Batch 4, that is
characterised by a higher percentage of NEU, exhibited a
slightly lower dissolution rate than Batch 3.
Long-Term Stability of the Samples
The long-term stability of the GLB solid dispersions was
evaluated by assessing the solid state stability and dissolution
rates. The mean geometric particle size of the samples under
evaluation remains unchanged during the time interval of
stability studies. In particular, the mean geometric particle size
of Batches 1–4, in spite of the particles being in the nanometric
range, did not significantly change (significance level P<0.05),
probably because of the presence of the polysorbate that
prevents the particle agglomeration. The DSC thermograms
did not show differences compared to the same sample at time
0 (Table II), while XRP diffraction analysis showed a slight
increase in the crystallinity degree for Batches 1 and 2, which
were not completely amorphous at time 0 (Table II). Thus,
when some crystalline nuclei were present in the mixture, it
was possible to observe a tendency to crystallization that on
the contrary was not observed when the mixture was
completely amorphous. The completely amorphous samples
proved to be highly stable after 1 year, and no crystallization
was observed with time. IDR analysis was repeated again, and
no significant changes in IDRs were observed with the excep-
tion of Batches 1 and 2, which showed slightly decreased
IDRs, certainly as a consequence of the crystallization
(Table III).
CONCLUSIONS
A new and very interesting approach for improving
glibenclamide particle dissolution was achieved by dispers-
ing glibenclamide in Neusilin® UFL2, an amorphous syn-
thetic form of magnesium aluminometasilicate, in presence
of polysorbate 80. The drug dispersion into the amor-
phous material favored the formation of stable amorphous
solid dispersions (Batches 3 and 4) and also the formation
of very small particles of nearly 200–400 nm. The small
particle size as well as the dispersion in an insoluble
amorphous matrix improved the drug dissolution from
particles. The best particle dissolution of Batch 3 makes
it possible to select it as the best sample. Its excellent
dissolution profile, together with its good physical stability
holds promise for interesting applications in the develop-
ment of solid dosage forms of glibenclamide with in-
creased bioavailability.
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Table III. Intrinsic Dissolution Rates (IDRs) of Glibenclamide Samples Determined at Time Zero (t0) and After Storage for 12 Months (t1)









NCs 2.8089E-05 0.9989 2.1163E-07 2.8033E-05 0.9987 2.1121E-07
Batch 1 5.5955E-05 0.9897 4.2157E-07 5.3020E-05 0.9995 3.9946E-07
Batch 2 6.3501E-05 0.9991 4.7842E-07 5.3551E-05 0.9990 4.0346E-07
Batch 3 7.0209E-05 0.9988 5.2860E-07 7.0293E-05 0.9991 5.2959E-07
Batch 4 6.9566E-05 0.9985 5.2411E-07 6.9119E-05 0.9989 5.2075E-07
Fig. 5. Cumulative particle dissolution profile % of glibenclamide
native crystals (NCs) and Batches 1–4 in phosphate buffer pH 7.2
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